A Validation Study of a Taiwanese Version of the Brief Fatigue Inventory and the MD Anderson Symptom Inventory

Principal Investigator: Xin Shelley Wang, M.D., M.P.H.

Common symptoms of cancer and cancer treatment significantly impair the function and quality of life of patients. However, some of them are often under-treated because of lack of a validated instrument. The current status of symptom management for cancer has been studied in some countries, but not in Taiwan. The goal of this study is to establish the validation of two symptom assessment instruments and look at symptoms related to cancer and its treatment in Taiwan.

Specific Objectives

  • To validate a Japanese version of the Brief Fatigue Inventory utilizing patients who currently have different degrees of cancer-related fatigue, and thus produce an instrument that is sensitive, reliable and valid for use in future clinical trials assessing fatigue (Complete)
  • To validate a Japanese version of MD Anderson Symptom Inventory (MDASI) in patients with different cancer types, who have undergone various treatments, and who have different levels of severity of symptoms other than fatigue (Complete)


This validation study included a one-time survey of a sample of outpatients and inpatients with both hematological and solid tumor type diseases at hospitals in the National Cancer Center Hospital and Hospital East, Japan.


Instruments included the Brief Fatigue Inventory (BPI) and the MD Anderson Symptom Inventory (MDASI), Cancer Fatigue Scale, EORTC QLQ-C30 and the Profile of Mood States (POMS).

For more information

Contact Xin Shelley Wang, M.D., M.P.H., at swong@mdanderson.org